[Recently recognized ophthalmic complications of systemic treatments].
The ocular side effects of systemic treatments are numerous and sometimes severe. The prescriber and the ophthalmologist should be aware of ocular side effects of systemic treatments in order to inform their patients accordingly, implement appropriate ophthalmological monitoring and/or treatment and if necessary, adapt the therapeutic management. In this review, we describe the recently recognized ophthalmic complications of systemic treatments, except for optic neuropathies.
Service d'ophtalmologie, hôpital de Bicêtre, Assistance publique-Hôpitaux de Paris, DHU vision et handicaps, université Paris-Sud, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France. Electronic address: antoine.rousseau@aphp.fr.
A
A
Rousseau
Service d'ophtalmologie, hôpital de Bicêtre, Assistance publique-Hôpitaux de Paris, DHU vision et handicaps, université Paris-Sud, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France.
M
M
Labetoulle
D000970:Antineoplastic Agents / Q000009:adverse effects; D005128:Eye Diseases / Q000139:chemically induced*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects
D000970:Antineoplastic Agents; D007155:Immunologic Factors
Biphosphonate; Bisphosphonate; Cancer target therapy; Effets indésirables oculaires; Etanercept; Fingolimod; Inhibiteurs de la phosphodiestérase; Interféron; Nicorandil; Ocular adverse effects; Phosphodiesterase inhibitors; Thérapies ciblées anticancéreuses; Topiramate; Étanercept